Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Brain Neoplasms 6Prostatic Neoplasms 5Glioma 2Glioblastoma 2Disease 2Urinary Bladder Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1

Interventions

enzalutamide 94Magnetic Resonance Spectroscopy 86Specimen Handling 66Prednisone 66Androgen Antagonists 60Abiraterone Acetate 58apalutamide 56Radiosurgery 53darolutamide 48Radiotherapy 47Leuprolide 47abiraterone 46Docetaxel 43Pluvicto 32Radiation 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Biopsy 30Surveys and Questionnaires 29relugolix 28pembrolizumab 26gallium 68 PSMA-11 26Standard of Care 26Triptorelin Pamoate 25Goserelin 25bicalutamide 23Gonadotropin-Releasing Hormone 23Brachytherapy 21Carboplatin 20cabazitaxel 19X-Rays 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Prostatic Neoplasms × fluciclovine F-18 × 1 year × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT05053152 2026-05-04

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NRG Oncology

Phase 2 Active not recruiting
194 enrolled
Genitourinary

Prostatic Neoplasms

NCT05722925 2025-11-14

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

OHSU Knight Cancer Institute

Phase 4 Active not recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT06062745 2025-11-05

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Brigham and Women's Hospital

Phase 1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡